AHR and acromegaly: Older age, smaller tumor size, lower signal intensity on T2-weighted MRI, greater response to octreotide loading, DG type, mutations in the stimulatory G-protein α subunit, lower Ki-67 index, higher SSTR2 expression, no aryl hydrocarbon receptor interacting protein mutation, and paradoxical GH response to OGTT were considered fg-SRL efficacy factors for acromegaly [3, 4, 9].